中期FDG PET/CT在PSMA靶向放射性配体治疗中解决PSA-PSMA不一致的价值
本文报告2例转移性去势抵抗性前列腺癌患者在接受2周期177Lu-PSMA放射性配体治疗后,出现PSA升高但PSMA SPECT/CT显示肿瘤体积显著缩小的不一致现象。2周期后进行的18F-FDG PET/CT揭示了新的高代谢骨和内脏病灶,证实疾病进展,两例均提前终止PSMA靶向治疗。
要点
- PSMA治疗后PSA升高而PSMA SPECT/CT显示缓解时,应警惕PSA-PSMA不一致。
- 18F-FDG PET/CT可揭示PSMA SPECT/CT未显示的高代谢进展病灶。
- FDG PET/CT有助于避免无效PSMA靶向放射性配体治疗的继续。
核心结论
- 18F-FDG PET/CT可能解决PSA与PSMA显像不一致的问题,并有助于防止无效PSMA靶向放射性配体治疗的继续。
研究设计与样本
- 病例报告,纳入2例转移性去势抵抗性前列腺癌患者,接受2周期177Lu-PSMA放射性配体治疗后出现PSA-PSMA不一致。
主要发现
- 2周期后177Lu-PSMA治疗后SPECT/CT显示PSMA来源肿瘤体积显著缩小,但PSA水平进展。
- 2周期后18F-FDG PET/CT显示新的高代谢骨和内脏病灶,符合疾病进展。
- 两例患者均提前终止了PSMA靶向放射性配体治疗。
临床怎么用
- 对于PSMA靶向放射性配体治疗中出现PSA升高但PSMA SPECT/CT显示缓解的患者,可考虑行18F-FDG PET/CT以明确疾病状态。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PSMA-targeted radioligand therapy (RLT) is effective in metastatic castration-resistant prostate cancer, but interpretation is challenging when PSA rises despite apparent response on post-therapy 177 Lu-PSMA SPECT/CT. We present 2 patients with this PSA-PSMA discordance after 2 cycles: 177 Lu-PSMA post-therapy SPECT/CT showed a significant reduction in PSMA-derived tumor volume, yet PSA levels progressed. 18 F-FDG PET/CT performed after 2 cycles clarified disease status by revealing new hypermetabolic skeletal and visceral lesions, consistent with progression. PSMA-targeted RLT was discontinued early in both cases. 18 F-FDG PET/CT may resolve discordant PSA and PSMA findings and help prevent futile continuation of ineffective PSMA‑targeted RLT.
引用
- Kassas M, Artigas C, Refalo N, et al. Added Value of Interim FDG PET/CT in Resolving PSA-PSMA Discordance during PSMA-targeted Radioligand Therapy. Clin Nucl Med. 2025. PMID: 41490309. doi:10.1097/RLU.0000000000006260
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。